Genisphere

NEW YORK (GenomeWeb News) – Genisphere said today it has licensed its 3DNA Signal Amplification technology to Chembio Diagnostics.

Quest Diagnostics has been awarded US Patent No. 8,346,485, "Methods and apparatuses for estimating initial target nucleic acid concentration in a sample by modeling background signal and cycle-dependent amplification efficiency of a polymerase chain reaction."

Genisphere and the Lankenau Institute for Medial Research said this week that they are expanding their collaboration on the development of microRNA biomarkers for ulcerative colitis to include Crohn's disease and other inflammatory bowel disorders.

NEW YORK (GenomeWeb News) –Genisphere and the Lankenau Institute for Medical Research today said that they have expanded their research collaboration aimed at identifying microRNA biomarkers to include Crohn's Disease and other inflammatory bowel disorders.

Hahn-Schickard-Gesellschaft of Villingen-Schwenningen, Germany, has received US Patent No.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Affymetrix plans to offer Genisphere's miRNA reagents for use with its GeneChip miRNA 2.0 Arrays under a new license agreement, Affy said today.

Genisphere said this week that it has signed deals licensing its RNA target amplification and FlashTag Biotin microRNA labeling technologies to Affymetrix.

Quest Diagnostics, Albert Einstein College of Medicine, Riken, Genisphere, Stanford, DNA Electronics, US Genomics, Qiagen, and others awarded US patents.

Pages

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.